SCHEMBL15072744

SCHEMBL15072744

CC(=O)Nc1cc(-n2cc(-c3ccccc3)c(-c3nc[nH]n3)c2)c(C)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.38
ABL1 P00519 2/20 0.37
ADORA3 P0DMS8 3/20 0.37
ADORA1 P30542 2/20 0.37
ADORA2A P29274 1/20 0.37
JAK1 P23458 2/20 0.36
TYK2 P29597 2/20 0.36
GCK P35557 1/20 0.36
CRBN Q96SW2 1/20 0.36
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
EGFR P00533 1/20 0.35
CDK5 Q00535 2/20 0.35
CDK5R1 Q15078 2/20 0.35
MAPK13 O15264 1/20 0.35
BRAF P15056 1/20 0.35
KDR P35968 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15050758 0.88 PIK3C3 (0.37) PIK3C3ABL1ADORA3ADORA2AJAK1
SCHEMBL15072386 0.82 PIK3C3 (0.38) PIK3C3ABL1ADORA3ADORA1ADORA2A
SCHEMBL15072397 0.79 MAPK1 (0.37) ABL1JAK1TYK2MAPK14TUBB4A
SCHEMBL15051877 0.79 ABL1 (0.36) PIK3C3ABL1ADORA3JAK1TYK2
SCHEMBL15051063 0.78 S1PR4 (0.35) PIK3C3ABL1ADORA1ADORA2AJAK1
SCHEMBL15051168 0.78 ABL1 (0.34) PIK3C3ABL1JAK1TYK2CRBN
SCHEMBL15051329 0.78 NPC1 (0.40) ABL1TYK2GSK3BTUBB4ATUBB
SCHEMBL15051721 0.78 ABL1 (0.38) ABL1ADORA3ADORA1JAK1TYK2
SCHEMBL15050840 0.77 ABL1 (0.36) PIK3C3ABL1EGFRKDR
SCHEMBL15051589 0.76 NPC1 (0.32) PIK3C3ABL1ADORA3JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 PIK3C3 73/4885ABL1 801/4885ADORA3 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.